Evidence map›Paper›PMID 40938666›Full record

ArticleJournal of the American Society of Nephrology : JASN2026

Effect of Finerenone on Morbidity and Mortality in CKD.

John W Ostrominski, Gerasimos Filippatos, Brian L Claggett, Zi Michael Miao, Akshay S Desai, Pardeep S Jhund, Alasdair Henderson, Katja Rohwedder, Meike D Brinker, Andrea Scalise and 14 more

Abstract read
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Finerenone in CKD from Estimands to Clinical Interpretability under Competing Risk.Journal of the American Society of Nephrology : JASN · 2026
    Article
  4. Finerenone in CKD: Enhancing the Evidence Base in Real-World Contexts.Journal of the American Society of Nephrology : JASN · 2026
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

John W OstrominskiCardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-2866-9414
Gerasimos FilippatosSchool of Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.ORCID 0000-0002-5640-0332
Brian L ClaggettCardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0009-0009-1748-4340
Zi Michael MiaoCardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-2377-1444
Akshay S DesaiCardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-1443-0701
Pardeep S JhundBritish Heart Foundation Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, Scotland, United Kingdom.ORCID 0000-0003-4306-5317
Alasdair HendersonBritish Heart Foundation Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, Scotland, United Kingdom.ORCID 0000-0002-8903-4906
Katja RohwedderBayer AG, Global Medical Affairs, Berlin, Germany.
Meike D BrinkerBayer AG, Research and Development, Pharmaceuticals, Wuppertal, Germany.ORCID 0000-0002-1560-9535
Andrea ScaliseCardiology and Nephrology Clinical Development, Bayer Hispania S.L., Barcelona, Spain.ORCID 0000-0002-9367-5773
Patrick SchloemerBayer AG, Research and Development, Pharmaceuticals, Berlin, Germany.ORCID 0009-0004-7787-5662
Carolyn S P LamNational Heart Centre Singapore and Duke-National University of Singapore, Singapore.ORCID 0000-0003-1903-0018
Michele SenniUniversity of Milano-Bicocca ASST Papa Giovanni XXIII Hospital, Bergamo, Italy.ORCID 0000-0001-5502-7882
Sanjiv J ShahFeinberg Cardiovascular Research Institute, Northwestern University Feinberg School of Medicine, Chicago, Illinois.ORCID 0000-0002-5655-8201
Adriaan A VoorsGroningen Heart Failure Research Institute, University of Groningen, Groningen, The Netherlands.
Faiez ZannadUniversity of Lorraine, Clinical Investigation Centre, Nancy, France.ORCID 0000-0001-7456-1570
Peter RossingSteno Diabetes Center Copenhagen, Herlev, Denmark.ORCID 0000-0002-1531-4294
Luis M RuilopeHospital 12 de Octubre, Madrid, Spain.ORCID 0000-0001-6278-7951
Stefan D AnkerDepartment of Cardiology (CVK), German Heart Center Charité, German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin, Berlin, Germany.
Bertram PittDepartment of Medicine, University of Michigan, Ann Arbor, Michigan.
Rajiv AgarwalIndiana University School of Medicine, Indianapolis, Indiana.ORCID 0000-0001-8355-7100
John J V McMurrayBritish Heart Foundation Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, Scotland, United Kingdom.ORCID 0000-0002-6317-3975
Scott D SolomonCardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0003-3698-9597
Muthiah VaduganathanCardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0003-0885-1953

Funding

Bayer
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cardiovascular diseasecardiovascular eventsCKDdiabetesdiabetic kidney diseaseheart failure

Identifiers

PMID40938666
PMCPMC12890010

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.